Leonard BM; Department of Pathology & Laboratory Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA. Shuvaev VV; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. BullockTA; Department of Pathology & Laboratory Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA. Galpayage Dona KNU; Department of Pathology, Immunology & Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA. Muzykantov VR; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Andrews AM; Department of Pathology & Laboratory Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA.; Department of Pathology, Immunology & Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA.; Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA. Ramirez SH; Department of Pathology & Laboratory Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA.; Department of Pathology, Immunology & Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA.; Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA.; Shriner's Hospital for Children, Philadelphia, PA 19312, USA.
Activation of CB2R by synthetic CB2R agonist, PM289, improves brain endothelial barrier properties, decreases inflammatory response and enhances endothelial repair.
Autorzy:
BullockTA; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.; Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. Galpayage Dona KNU; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. Hale JF; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. Morales P; Medicinal Chemistry Institute, Spanish National Research Council, Madrid, Spain. Jagerovic N; Medicinal Chemistry Institute, Spanish National Research Council, Madrid, Spain. Andrews AM; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.; Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. Ramirez SH; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.; Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.; Shriner's Hospital for Children, Philadelphia, PA, USA.
Pokaż więcej
Źródło:
NeuroImmune pharmacology and therapeutics [NeuroImmune Pharm Ther] 2023 Oct 16; Vol. 2 (4), pp. 387-400. Date of Electronic Publication: 2023 Oct 16 (Print Publication: 2023).
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
